Get the Stockscreener App
1.68
0.60%
0.01
Gri Bio Inc stock is traded at $1.68, with a volume of 87,180.
It is up +0.60% in the last 24 hours and down -12.04% over the past month.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
See More
Previous Close:
$1.67
Open:
$1.7
24h Volume:
87,180
Relative Volume:
0.08
Market Cap:
$4.23M
Revenue:
-
Net Income/Loss:
$-8.26M
P/E Ratio:
-0.0313
EPS:
-53.609
Net Cash Flow:
$-12.17M
1W Performance:
-5.08%
1M Performance:
-12.04%
6M Performance:
-19.62%
1Y Performance:
-90.02%
1-Day Range:
$1.596
$1.70
1-Week Range:
$1.58
$1.77
52-Week Range:
$1.10
$16.95
Gri Bio Inc Stock (GRI) Company Profile
Name
Gri Bio Inc
Sector
Industry
Phone
(619) 400-1171
Address
2223 AVENIDA DE LA PLAYA, LA JOLLA
Compare GRI with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GRI
Gri Bio Inc
|
1.68 | 4.20M | 0 | -8.26M | -12.17M | -53.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
417.00 | 107.10B | 11.70B | 3.68B | 3.50B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
644.19 | 66.00B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
434.56 | 55.95B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
832.35 | 51.19B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
186.88 | 38.98B | 447.02M | -1.18B | -906.14M | -6.1812 |
Gri Bio Inc Stock (GRI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-24 | Initiated | H.C. Wainwright | Buy |
Gri Bio Inc Stock (GRI) Latest News
GRI Bio Inc. stock daily chart insightsJobs Report & Technical Pattern Based Buy Signals - newser.com
Technical analysis overview for GRI Bio Inc. stockJuly 2025 Final Week & Real-Time Volume Spike Alerts - newser.com
Will GRI Bio Inc. stock maintain dividend yieldEarnings Growth Report & Reliable Breakout Stock Forecasts - fcp.pa.gov.br
Visual analytics tools that track GRI Bio Inc. performanceVolume Spike & Technical Confirmation Trade Alerts - newser.com
Is GRI Bio Inc. stock recession proofWeekly Profit Report & Daily Profit Maximizing Tips - fcp.pa.gov.br
Is GRI Bio Inc. meeting your algorithmic filter criteriaDollar Strength & AI Optimized Trade Strategies - newser.com
How GRI Bio Inc. stock performs in rate cut cyclesQuarterly Trade Review & Community Consensus Trade Alerts - newser.com
Analyzing net buyer seller activity in GRI Bio Inc.July 2025 Spike Watch & Low Risk High Win Rate Stock Picks - newser.com
Why GRI Bio Inc. stock is considered a top pickPortfolio Risk Report & Growth Focused Stock Pick Reports - newser.com
Will GRI Bio Inc. stock see insider buyingTrade Risk Assessment & Capital Efficiency Focused Ideas - newser.com
How supply chain issues affect GRI Bio Inc. stockJuly 2025 Summary & Daily Technical Forecast Reports - newser.com
What does recent volatility data suggest for GRI Bio Inc.Earnings Recap Report & Low Risk High Win Rate Stock Picks - newser.com
Using economic indicators to assess GRI Bio Inc. potentialEarnings Overview Summary & Free High Accuracy Swing Entry Alerts - newser.com
Will GRI Bio Inc. stock outperform value stocksJuly 2025 Weekly Recap & Stock Portfolio Risk Control - newser.com
Smart tools for monitoring GRI Bio Inc.’s price actionBuy Signal & Fast Moving Stock Watchlists - newser.com
Backtesting results for GRI Bio Inc. trading strategiesPortfolio Return Report & Long-Term Safe Investment Ideas - newser.com
Gri Bio Inc Stock (GRI) Financials Data
Revenue
Net Income
Cash Flow
EPS
6.82%
1.34%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):